<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04667533</url>
  </required_header>
  <id_info>
    <org_study_id>DESI.20.001</org_study_id>
    <nct_id>NCT04667533</nct_id>
  </id_info>
  <brief_title>Desidustat in the Treatment of Chemotherapy Induced Anemia</brief_title>
  <official_title>A Phase 1, Open-Label, Single Dose, Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Desidustat for Treatment of Anemia in Patients Receiving Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cadila Healthcare Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cadila Healthcare Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, Open-label, Single Dose, Study to Evaluate the Safety, Tolerability and&#xD;
      Pharmacokinetics of Desidustat for treatment of anemia in patients receiving chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of up to approximately 24 patients will be enrolled to receive Desidustat in an&#xD;
      open-label manner.&#xD;
&#xD;
      The study is divided into three cohorts as given below:&#xD;
&#xD;
        1. Cohort I: Single-dose 100 mg&#xD;
&#xD;
        2. Cohort II: Single-dose 150 mg&#xD;
&#xD;
        3. Cohort III: Single-dose 200 mg&#xD;
&#xD;
      Note:- After evaluation of PK data of 100 mg dose cohort, next cohort with higher dose will&#xD;
      be decided. Maximum dose of Desidustat will not be exceeded than 200 mg.&#xD;
&#xD;
      First cohort will be given 100 mg single dose of Desidustat. On completion of safety and PK&#xD;
      evaluation of first cohort,the next cohort with escalated single dose (150 mg) of Desidustat&#xD;
      will be initiated. Similar way third cohort with 200 mg single dose will be initiated after&#xD;
      safety evaluation of 150 mg cohort data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 11, 2020</start_date>
  <completion_date type="Anticipated">September 10, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 6, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate Adverse event of Desidustat following a single oral dose of 100 or 150 or 200 mg in patients with chemotherapy induced anemia.</measure>
    <time_frame>Change from Baseline to Day 7 and Day 30</time_frame>
    <description>The Common Terminology Criteria for Adverse Event (CTCAE) (Version 4.03 or higher) system will be used for reporting and grading</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of hemoglobin measurement from baseline</measure>
    <time_frame>Change from baseline to Day 7 and Day 30</time_frame>
    <description>a single oral dose of 100 or 150 or 200 mg in patients with chemotherapy induced anemia.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>Change from Baseline to 72 hours in blood</time_frame>
    <description>a single oral dose of 100 or 150 or 200 mg in patients with chemotherapy induced anemia.&#xD;
To compute pharmacokinetics, blood PK samples will be collected at pre-dose (&lt;-0.5 h) and then 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0, 12.0, 24.0, 48.0 and 72.0 hour post the single dose administration.&#xD;
Patients will be discharged on Day 1 and provide Day 2 and Day 3 PK as an outpatient visit for PK draws.</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to reach maximum plasma concentration (Tmax)</measure>
    <time_frame>Change from Baseline to 72 hours in blood</time_frame>
    <description>a single oral dose of 100 or 150 or 200 mg in patients with chemotherapy induced anemia.&#xD;
To compute pharmacokinetics, blood PK samples will be collected at pre-dose (&lt;-0.5 h) and then 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0, 12.0, 24.0, 48.0 and 72.0 hour post the single dose administration.&#xD;
Patients will be discharged on Day 1 and provide Day 2 and Day 3 PK as an outpatient visit for PK draws.</description>
  </other_outcome>
  <other_outcome>
    <measure>Area under the curve from the time of dosing to the last measurable concentration (AUC0-t)</measure>
    <time_frame>Change from Baseline to 72 hours in blood</time_frame>
    <description>a single oral dose of 100 or 150 or 200 mg in patients with chemotherapy induced anemia.&#xD;
To compute pharmacokinetics, blood PK samples will be collected at pre-dose (&lt;-0.5 h) and then 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0, 12.0, 24.0, 48.0 and 72.0 hour post the single dose administration.&#xD;
Patients will be discharged on Day 1 and provide Day 2 and Day 3 PK as an outpatient visit for PK draws.</description>
  </other_outcome>
  <other_outcome>
    <measure>Terminal half life (t1/2)</measure>
    <time_frame>Change from Baseline to 72 hours in blood</time_frame>
    <description>a single oral dose of 100 or 150 or 200 mg in patients with chemotherapy induced anemia.&#xD;
To compute pharmacokinetics, blood PK samples will be collected at pre-dose (&lt;-0.5 h) and then 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0, 12.0, 24.0, 48.0 and 72.0 hour post the single dose administration.&#xD;
Patients will be discharged on Day 1 and provide Day 2 and Day 3 PK as an outpatient visit for PK draws.</description>
  </other_outcome>
  <other_outcome>
    <measure>Elimination rate constant (λz)</measure>
    <time_frame>Change from Baseline to 72 hours in blood</time_frame>
    <description>a single oral dose of 100 or 150 or 200 mg in patients with chemotherapy induced anemia.&#xD;
To compute pharmacokinetics, blood PK samples will be collected at pre-dose (&lt;-0.5 h) and then 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0, 12.0, 24.0, 48.0 and 72.0 hour post the single dose administration.&#xD;
Patients will be discharged on Day 1 and provide Day 2 and Day 3 PK as an outpatient visit for PK draws.</description>
  </other_outcome>
  <other_outcome>
    <measure>Clearance (CL)</measure>
    <time_frame>Change from Baseline to 72 hours in blood</time_frame>
    <description>a single oral dose of 100 or 150 or 200 mg in patients with chemotherapy induced anemia.&#xD;
To compute pharmacokinetics, blood PK samples will be collected at pre-dose (&lt;-0.5 h) and then 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0, 12.0, 24.0, 48.0 and 72.0 hour post the single dose administration.&#xD;
Patients will be discharged on Day 1 and provide Day 2 and Day 3 PK as an outpatient visit for PK draws.</description>
  </other_outcome>
  <other_outcome>
    <measure>Volume of distribution (Vd)</measure>
    <time_frame>Change from Baseline to 72 hours in blood</time_frame>
    <description>a single oral dose of 100 or 150 or 200 mg in patients with chemotherapy induced anemia.&#xD;
To compute pharmacokinetics, blood PK samples will be collected at pre-dose (&lt;-0.5 h) and then 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0, 12.0, 24.0, 48.0 and 72.0 hour post the single dose administration.&#xD;
Patients will be discharged on Day 1 and provide Day 2 and Day 3 PK as an outpatient visit for PK draws.</description>
  </other_outcome>
  <other_outcome>
    <measure>Amount recovered in Urine</measure>
    <time_frame>Change from baseline to 24 hours in urine</time_frame>
    <description>Urine PK collection will occur relative to dosing of Desidustat at pre-dose (within 2 hours before dosing) and then at the proposed time points (0-6, 6-12 and 12-24 hr) for clearance. Desidustat and the drug metabolite in urine and additional assay may be required.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent recovered in urine</measure>
    <time_frame>Change from baseline to 24 hours in urine</time_frame>
    <description>Urine PK collection will occur relative to dosing of Desidustat at pre-dose (within 2 hours before dosing) and then at the proposed time points (0-6, 6-12 and 12-24 hr) for clearance. Desidustat and the drug metabolite in urine and additional assay may be required.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Anemia of Chronic Kidney Disease</condition>
  <condition>Chemotherapy Effect</condition>
  <arm_group>
    <arm_group_label>Desidustat tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desidustat</intervention_name>
    <description>A total of 24 participants will be enrolled.&#xD;
The study is divided into three cohorts as given below:&#xD;
Cohort I: Single-dose 100 mg&#xD;
Cohort II: Single-dose 150 mg&#xD;
Cohort III: Single-dose 200 mg</description>
    <arm_group_label>Desidustat tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of non-myeloid malignancy.&#xD;
&#xD;
          2. Ability to comprehend and willingness to sign a written ICF for the study.&#xD;
&#xD;
          3. Male and Female patients at least 18 years old at the time of signing the ICF.&#xD;
&#xD;
          4. Anemia caused by cancer treatment (chemotherapy) defined as Hb ≤11.0 g/dL at&#xD;
             screening.&#xD;
&#xD;
          5. Subjects with eGFR &gt;60 mL/min/1.73 meter sequre at screening.&#xD;
&#xD;
          6. Weight should be ≥50 kg.&#xD;
&#xD;
          7. Willingness to participate after informed consent.&#xD;
&#xD;
          8. Females will not be pregnant or lactating, and females of childbearing potential and&#xD;
             males will agree to use contraception.&#xD;
&#xD;
          9. Ability to swallow and retain oral medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known hypersensitivity to Desidustat and excipients in the investigational drug&#xD;
             product.&#xD;
&#xD;
          2. History or presence of significant alcoholism, smoking or drug of abuse within 30 days&#xD;
             at the time of screening.&#xD;
&#xD;
          3. History of RBC transfusion &lt;4 weeks prior enrollment.&#xD;
&#xD;
          4. History or presence of any clinically significant electrocardiogram abnormalities&#xD;
             during screening.&#xD;
&#xD;
          5. Cardiovascular risks, such as myocardial infarction, stroke, heart failure or&#xD;
             thromboembolic event (e.g., deep vein thrombosis (DVT) or pulmonary embolism) within&#xD;
             previous 6 months of screening&#xD;
&#xD;
          6. Major illness and/or major surgery in the last 3 months.&#xD;
&#xD;
          7. Planned elective surgery during the study&#xD;
&#xD;
          8. Receiving or has received any investigational drug within the 30 days before receiving&#xD;
             Desidustat.&#xD;
&#xD;
          9. Any participants with poor peripheral venous access.&#xD;
&#xD;
         10. A positive test result for Human Immunodeficiency Virus (HIV), hepatitis B surface&#xD;
             antigen (HBsAg) or hepatitis C virus (HCV) antibody at screening visit.&#xD;
&#xD;
         11. Female patients with following criteria will not be recruited:&#xD;
&#xD;
               -  History of pregnancy or lactation in the past 3 months&#xD;
&#xD;
               -  Fertile female volunteers not protected against pregnancy by adequate long-term&#xD;
                  antifertility measures&#xD;
&#xD;
               -  History of less than 1 year of menopause and not using adequate long-term&#xD;
                  anti-fertility measures&#xD;
&#xD;
               -  Using hormone replacement therapy&#xD;
&#xD;
               -  Unable to give assurance for protection against pregnancy for 3 months after the&#xD;
                  participation in this trial&#xD;
&#xD;
               -  Positive serum β-hCG level at the screening visit&#xD;
&#xD;
         12. Abnormal baseline laboratory investigations as follows:&#xD;
&#xD;
               -  WBC count ≤ 3 x 103/uL&#xD;
&#xD;
               -  Platelets count ≤ 100 x 103/uL&#xD;
&#xD;
               -  Bilirubin ≥ 1.5 mg/dL&#xD;
&#xD;
               -  ALT and/or AST ≥ 2.5 times of the ULN.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Deven Parmar, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cadila Healthcare Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr Kevin Kansagra, MD</last_name>
    <phone>02717665555</phone>
    <phone_ext>279</phone_ext>
    <email>kevinkumar.kansagra@zyduscadila.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dr Balaji More, DM</last_name>
    <phone>02717665555</phone>
    <phone_ext>451</phone_ext>
    <email>balaji.more@zyduscadila.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HCG Manavata Cancer Centre,</name>
      <address>
        <city>Nashik</city>
        <state>Mahar Ashtra</state>
        <zip>422002</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Rajnish Nagarkar</last_name>
      <phone>9823061929</phone>
      <email>drraj@manavatacancercentre.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 9, 2020</study_first_submitted>
  <study_first_submitted_qc>December 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2020</study_first_posted>
  <last_update_submitted>December 11, 2020</last_update_submitted>
  <last_update_submitted_qc>December 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chemotherapy induced Anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

